Gut Hormone Cells Keep Your Intestinal Barrier Intact — And Their Peptides Could Treat Leaky Gut

Enteroendocrine cells — hormone-producing cells in the gut lining — are required to maintain a healthy intestinal barrier. When human intestinal organoids were genetically engineered to lack these cells, barrier function deteriorated in both stem cell-like and mature tissue. Adding the peptide hormones PYY (peptide tyrosine-tyrosine) and octreotide (a somatostatin analog) rescued barrier function both at baseline and in the presence of the inflammatory cytokine TNF. Surprisingly, the barrier improvement occurred without significant changes in tight junction protein levels, suggesting a novel mechanism.

Researchers grew human intestinal enteroids (miniature gut tissue models) on Transwell filters. They used genetic knockout to remove enteroendocrine cells and measured barrier function via transepithelial electrical resistance and paracellular permeability assays. They then supplemented the EEC-deficient cultures with PYY and octreotide to test whether these hormones could restore barrier function. Tight junction proteins were assessed by immunostaining and abundance measurements.

There are currently no drugs that directly strengthen the intestinal barrier — a central problem in inflammatory bowel disease, where a leaky gut drives a cycle of worsening inflammation. This study reveals that gut hormones PYY and somatostatin can directly improve barrier integrity, opening an entirely new therapeutic avenue for IBD and other conditions involving intestinal permeability.

Leaky gut is a central driver of inflammatory bowel disease and may play a role in many other conditions. Despite this, no current therapy directly targets intestinal barrier permeability. This study identifies gut peptide hormones as a previously unknown barrier-strengthening mechanism, potentially opening a new drug class. Notably, octreotide is already FDA-approved for other conditions, which could accelerate clinical testing for barrier repair.

This is an in-vitro study using human intestinal organoids, not living patients. While organoids are more representative than cell lines, they lack the immune cells, blood vessels, and microbiome present in a real gut. The study did not test other enteroendocrine hormones (like GLP-1 or GLP-2) that might also contribute. Dosing and timing that would be effective in human IBD patients are unknown.